Pharmacogenomic biomarkers hold great promise for the future of medicine and have been touted as a means to personalize prescriptions. Genetic biomarkers for disease susceptibility including both Mendelian and complex disease promise to result in improved understanding of the pathophysiology of disease, identification of new potential therapeutic targets, and improved molecular classification of disease. The rapid development of techniques in the area of genome analysis has facilitated identification of new pharmacogenomic biomarkers that can provide predictive tools for improved drug response and fewer adverse drug reactions.
Pharmacovigilance and Pharmacoepidemiology is a scholarly journal maintaining high standards of Pharmacoepidemiology Researches. This Journal runs with scientific excellence and propagates the peer review process very quickly.